Skip to search formSkip to main contentSkip to account menu

BIIB021

Known as: BIIB-021 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

HSP90 inhibitor CNF2024

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The potent activation of Ca(2+)-activated K(+) current by NVP-AUY922 in the human pancreatic duct cell line (PANC-1) possibly independent of heat shock protein 90 inhibition.
2014
2014
Stimulation of electroporation‐induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922
Membrane electroporation (MEP) increases the electrical conductivity of the plasma membrane by addition of an external electrical… 
2014
2014
Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening
Hsp90 as a promising therapeutic target for the treatment of cancer has received great attention. Many Hsp90 inhibitors such as… 
2013
2013
Metabolism and Excretion of 6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 Inhibitor, in Rats and Dogs and Assessment of Its Metabolic Profile in Plasma of Humans
6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine (BIIB021), a synthetic HSP90 inhibitor, exhibited… 
2012
2012
In Vitro Metabolism of BIIB021, an Inhibitor of Heat Shock Protein 90, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans and Recombinant Human Cytochrome P450 Isoforms
Inhibition of heat shock protein 90 (HSP90) results in the degradation of oncoproteins that drive malignant progression and… 
2011
2011
Biogen Idec restructures, sharpens neurology focus
It seems odd for a company in good financial health to undertake a dramatic restructuring, but Biogen Idec of Weston… 
2010
2010
Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer
Background: BIIB021 is an oral, fully synthetic heat shock protein 90 inhibitor (Hsp90i) that selectively and potently inhibits… 
2009
2009
Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose:We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… 
2007
2007
BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
B161 Hsp90 is a widely-expressed molecular chaperone that functions in the maturation and stabilization of cellular proteins… 
2007
2007
Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor
A123 Hsp90 inhibitors hold great promise as anti-tumor therapies because Hsp90 is a critical chaperone of key proteins involved… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)